Dr. Stilgenbauer On Activity With Venetoclax In Patients With Cll

Dr. Stilgenbauer on Activity With Venetoclax in Patients With CLL

Venetoclax-Based Combination Therapy Chronic Lymphocytic Leukemia (CLL) - Dr. Stephan Stilgenbauer

Obinutuzumab, Ibrutinib, & Venetoclax in 17p / TP53 CLL - Dr. Stephan Stilgenbauer ASH 2022

Evolution of Chronic Lymphocytic Leukemia (CLL) to Richter's Syndrome - Dr. Stephan Stilgenbauer

Professor Stephan Stilgenbauer - What is chronic lymphocytic leukaemia (CLL) and how is it diagnosed

J&J Innovative Medicine EMEA

Can we afford to have CLL patients on a therapy for the rest of their lives?

VJHemOnc – Video Journal of Hematology & HemOnc

Resisitance mechanisms to venetoclax in patients with progressive CLL

ASH 2019 Interview -Prof Stephan Stilgenbauer and Deborah Sims- Updates on the management of CLL/SLL

Lymphoma Australia

Stephan Stilgenbauer

What should we be focusing on in CLL research?

VJHemOnc – Video Journal of Hematology & HemOnc

Sequential therapy and drug resistance in CLL in the era of targeted agents

VJHemOnc – Video Journal of Hematology & HemOnc

Key trials in CLL and designing a concept for treatment

VJHemOnc – Video Journal of Hematology & HemOnc

Chemo-free regimens continue for CLL

VJHemOnc – Video Journal of Hematology & HemOnc

Venetoclax for the Treatment of Elderly Patients With CLL

Targeted Oncology

Investigating the safety and efficacy of re-treating CLL patients with venetoclax-based regimens

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL

Dr. Awan Discusses Venetoclax in CLL

Ideal patient for Venetoclax/Obinutuzumab combination | Dr. Jeff Sharman | Oncology Brothers #2023

OncBrothers: Practice-Changing Cancer Discussions

Dr. Redner on the Activity of Venetoclax in AML

Update on Venetoclax for CLL